XNAS
PCRX
Market cap1.43bUSD
Oct 08, Last price
36.39USD
1D
44.40%
1Q
42.82%
Jan 2017
12.66%
IPO
417.64%
Name
Pacira Biosciences Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Key people
Independent Chairman of the Board · since 2025
Chief Executive Officer, Director · since 2024
Shawn Cross
Chief Financial Officer · since 2024
Daryl Gaugler
Executive Vice President - Commercial Operations · since 2025
Lauren Riker
Senior Vice President - Finance, Principal Accounting Officer · since 2024
Kristen Williams
Chief Administrative Officer, Secretary · since 2014
Krys Corbett
Chief Business Officer · since 2025
Jonathan Slonin
Chief Medical Officer · since 2023
Brendan Teehan
Chief Commercial Officer · since 2025
Marcelo Bigal
Independent Director · since 2023
Independent Director · since 2023
Christopher Christie
Independent Director · since 2022
Mark Froimson
Independent Director · since 2018
Independent Director · since 2026
Mark Kronenfeld
Independent Director · since 2013
Independent Director · since 2023
Alethia Young
Independent Director · since 2023
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
5401 West Kennedy Boulevard
Suite 890
Tampa, FL 33609
US
Suite 890
Tampa, FL 33609
US
Previous name
Pacira Pharmaceuticals, Inc
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||